Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance

Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer

Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals

Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals

Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors

Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors